XClose

Psychiatry

Home
Menu

Molecular Psychiatry Laboratory

Introduction

The Molecular Psychiatry Laboratory has been identifying genes increasing susceptibility for bipolar disorder, schizophrenia, alcohol misuse disorders and dementia using family linkage and genetic association studies. The fundamental aim of the research is to characterise the DNA variants that increase disease susceptibility by causing abnormalities in the structure or function of the proteins that these genes encode. With this information it will be possible to create new treatments or prevention strategies. 

Our Research Interests

Our research interests include genetics of schizophrenia, bipolar disorder and alcoholism, pharmacogenomics and design of new antipsychotic drugs.

Rizig et al (2012) Clozapine Haloperidol Gene Expression Study

Supplemental data for:

 

A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia. Mie A Rizig, Andrew McQuillin, Aylwin Ng, Michelle Robinson, Andrew Harrison, Marketa Zvelebil, Steve P Hunt, Hugh MD Gurling

The full lists of genes with changed expression from the three experiments with the corresponding t-test p values and fold changes as well as GO ontology hits and affected pathways can be downloaded using the links below:

 

Work carried out in the laboratory

Research in the Molecular Psychiatry Laboratory has used genetics as a method to understand the abnormal neurobiology causing schizophrenia, affective disorders and alcoholism. The Molecular Psychiatry Laboratory has completed genome wide linkage scans on family samples of schizophrenia, bipolar disorder and Tourette syndrome in order to localise susceptibility genes to specific regions of chromosomes. 

Genome Wide Association scans with SNP arrays have been completed on schizophrenia, bipolar disorder, alcohol dependence including sub samples Wernicke Korsakov's syndrome and alcoholic cirrhosis of the liver.  

Families of glutamate receptor genes as well as calcium channel genes have now been implicated in schizophrenia as well as bipolar disorder. A second major effort in the Molecular Psychiatry Laboratory concerns the use of systems biology and pharmacogenomics to point the way to new drug and preventive strategies for the psychoses.